Molecular Theranostic Agent with Programmed Activation for Hypoxic Tumors

Area of Science:

• Oncology
• Pharmacology
• Biomedical Engineering

Background:

• Hypoxic tumors are resistant to conventional therapies.
• Developing targeted drug delivery systems is crucial for cancer treatment.
• Theranostic agents offer simultaneous diagnosis and therapy.

Purpose of the Study:

• To develop a small-molecule prodrug activated by tumor hypoxia.
• To enable simultaneous chemotherapy release and fluorescence imaging.
• To evaluate the therapeutic efficacy and targeting in hypoxic tumors.

Main Methods:

• Synthesis of a theranostic prodrug.
• In vitro testing under hypoxic conditions.
• Monitoring prodrug activation via fluorescence at 543 nm.
• Assessing therapeutic response and cancer cell labeling.

Main Results:

• The prodrug successfully released an active chemotherapeutic agent and a rhodol fluorophore under hypoxia.
• Prodrug activation was confirmed by fluorescence monitoring.
• Effective therapeutic response was observed.
• Selective fluorescence labeling of cancer cells overexpressing biotin receptors was achieved.

Conclusions:

• The developed theranostic prodrug is a promising strategy for treating chronic hypoxic tumors.
• The prodrug enables targeted drug delivery and imaging in hypoxic environments.
• This approach offers a dual modality for cancer therapy and diagnostics.